Evidence map›Paper›PMID 34088662›Full record

ArticleScience advances2021

PDLLA-Zn-nitrided Fe bioresorbable scaffold with 53-μm-thick metallic struts and tunable multistage biodegradation function.

Danni Shen, Haiping Qi, Wenjiao Lin, Wanqian Zhang, Dong Bian, Xiaoli Shi, Li Qin, Gui Zhang, Wenchao Fu, Kefei Dou and 8 more

Open access · goldAbstract read
In one paragraph

Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 63 citations in OpenAlex.

  1. First-in-human evaluation of a novel ultrathin sirolimus-eluting iron bioresorbable scaffold: 3-year outcomes of the IBS-FIM trial.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2023
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. A hierarchical MgFBioactive materials · 2025
    Article
  11. Early "Scars" and Long-Term Promise of Bioresorbable Scaffolds: A Decade of Evidence From SCAAR.Journal of the Society for Cardiovascular Angiography & Interventions · 2025
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 4 countries.

Danni ShenBeijing Advanced Innovation Center for Materials Genome Engineering and School of Materials Science and Engineering, Peking University, Beijing 100871, China.ORCID 0000-0001-9091-0435
Haiping QiNational and Local Joint Engineering Laboratory of Interventional Medical Biotechnology and System, Lifetech Scientific (Shenzhen) Co. Ltd., Shenzhen 518110, China.ORCID 0000-0002-7506-3407
Wenjiao LinNational and Local Joint Engineering Laboratory of Interventional Medical Biotechnology and System, Lifetech Scientific (Shenzhen) Co. Ltd., Shenzhen 518110, China.ORCID 0000-0002-6184-5942
Wanqian ZhangNational and Local Joint Engineering Laboratory of Interventional Medical Biotechnology and System, Lifetech Scientific (Shenzhen) Co. Ltd., Shenzhen 518110, China.
Dong BianBeijing Advanced Innovation Center for Materials Genome Engineering and School of Materials Science and Engineering, Peking University, Beijing 100871, China.ORCID 0000-0002-4025-6655
Xiaoli ShiNational and Local Joint Engineering Laboratory of Interventional Medical Biotechnology and System, Lifetech Scientific (Shenzhen) Co. Ltd., Shenzhen 518110, China.
Li QinNational and Local Joint Engineering Laboratory of Interventional Medical Biotechnology and System, Lifetech Scientific (Shenzhen) Co. Ltd., Shenzhen 518110, China.
Gui ZhangNational and Local Joint Engineering Laboratory of Interventional Medical Biotechnology and System, Lifetech Scientific (Shenzhen) Co. Ltd., Shenzhen 518110, China.
Wenchao FuNational and Local Joint Engineering Laboratory of Interventional Medical Biotechnology and System, Lifetech Scientific (Shenzhen) Co. Ltd., Shenzhen 518110, China.
Kefei DouDepartment of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.
Bo XuDepartment of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.ORCID 0000-0002-1165-7302
Zhenyuan YinBioMed-X Center, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing 100871, China.ORCID 0000-0001-5204-5970
Jiancun RaoAIM Lab, Maryland NanoCenter, University of Maryland, College Park, MD 20742, USA.ORCID 0000-0002-7486-1714
Mazeni AlwiPaediatric Cardiology, Institut Jantung Negara (National Heart Institute), 145, Jalan Tun Razak, Kuala Lumpur 50400, Malaysia.
Shuhan WangShen Zhen Testing Center of Medical Devices, Shenzhen 518057, China.
Yufeng ZhengBeijing Advanced Innovation Center for Materials Genome Engineering and School of Materials Science and Engineering, Peking University, Beijing 100871, China. yfzheng@pku.edu.cn zhangdeyuan@lifetechmed.com gaorunlin@citmd.com.ORCID 0000-0002-7402-9979
Deyuan ZhangNational and Local Joint Engineering Laboratory of Interventional Medical Biotechnology and System, Lifetech Scientific (Shenzhen) Co. Ltd., Shenzhen 518110, China. yfzheng@pku.edu.cn zhangdeyuan@lifetechmed.com gaorunlin@citmd.com.ORCID 0000-0001-9401-5032
Runlin GaoDepartment of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. yfzheng@pku.edu.cn zhangdeyuan@lifetechmed.com gaorunlin@citmd.com.ORCID 0000-0002-2425-2005
Lifetech Scientific (China) · CNPeking University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNFudan University · CNNational Heart Institute · MYThe Medical Device (United Kingdom) · GBUniversity of Maryland, College Park · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Balancing the biodegradability and mechanical integrity of a bioresorbable scaffold (BRS) with time after implantation to match the remodeling of the scaffolded blood vessel is important, but a key challenge in doing so remains. This study presents a novel intercalated structure of a metallic BRS by introducing a nanoscale Zn sacrificial layer between the nitrided Fe platform and the sirolimus-carrying poly(d,l-lactide) drug coating. The PDLLA-Zn-FeN BRS shows a multistage biodegradation behavior, maintaining mechanical integrity at the initial stage and exhibiting accelerated biodegradation at the subsequent stage in both rabbit abdominal aortas and human coronary arteries, where complete biodegradation was observed about 2 years after implantation. The presence of the nanoscale Zn sacrificial layer with an adjustable thickness also contributes to the tunable biodegradation of BRS and allows the reduction of the metallic strut thickness to 53 μm, with radial strength as strong as that of the current permanent drug-eluting stents.

Identifiers

PMID34088662
PMCPMC8177708
OpenAlexW3164358870

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.